RBC Maintains Outperform Rating on Ascendis Pharma (ASND) Amid Growth Targets

Core Insights - Ascendis Pharma A/S (NASDAQ:ASND) is recognized as a high-growth European stock, with RBC Capital raising its price target to $250 from $245 while maintaining an Outperform rating [1] Group 1: Market Potential - The European market for Ascendis Pharma A/S is projected to be significantly larger, with an estimated 150,000-200,000 patients compared to 70,000-90,000 in the U.S., although the complex payer system may require patience [2] - The company anticipates a revenue split of 60% from the U.S. and 40% from non-U.S. markets [2] Group 2: Financial Projections - Ascendis Pharma A/S aims for €500 million in operating cash flow for the current year and over €5 billion in top-line revenue by 2030, exceeding the consensus estimate of approximately €3.5 billion [3] - Yorvipath is expected to generate between €5 billion and €8 billion at its peak [3] Group 3: Company Overview - Ascendis Pharma A/S is a biopharmaceutical company focused on developing and distributing innovative treatments for unmet medical needs, particularly in oncology and endocrinology [3]